Lidbree (Lidocaine)

Lidocaine works by blocking voltage‑gated sodium channels on nerve cells, which prevents the rapid influx of sodium ions needed for depolarisation. This inhibition stops the transmission of nerve impulses, resulting in a reversible loss of sensation in the area where the drug is applied.

The appropriate dose of Lidbree is determined by the prescribing clinician based on the specific procedure, patient weight, and clinical setting. Dosage recommendations are not standardized in public literature and should be individualized by a qualified healthcare professional.

Safety data for Lidbree during pregnancy or lactation are limited. The decision to use lidocaine‑containing products in these populations should be made by the prescriber after weighing potential benefits against possible risks to the mother and fetus or infant.

To order Lidbree, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Lidbree (lidocaine) is an amide‑type local anesthetic with a rapid onset and moderate duration, often compared with bupivacaine, which has a longer duration but slower onset. Lidocaine is preferred when a quick, short‑acting block is needed, whereas bupivacaine may be chosen for procedures requiring prolonged anesthesia.

Lidbree should be stored below 25 °C in its original packaging, protected from moisture and direct light. The container must remain sealed until use, and any unused portion should be discarded according to local regulations for sterile pharmaceutical solutions.

Lidbree is administered by intracervical or intrauterine injection using a sterile technique. The healthcare professional injects the solution directly into the cervical tissue or uterine cavity, ensuring accurate placement to achieve effective local anesthesia for the intended procedure.

Serious risks associated with Lidbree include cardiovascular collapse, severe hypotension, arrhythmias, central nervous system toxicity such as seizures, and rare but life‑threatening allergic reactions (anaphylaxis). Immediate medical attention is required if any of these symptoms occur.

Lidbree should be avoided in patients with a known hypersensitivity to lidocaine or other amide‑type local anesthetics, those with severe cardiac conduction disorders, and individuals with uncontrolled epilepsy. Caution is also advised for patients on medications that significantly affect lidocaine metabolism.